A driver was impaired by a potent synthetic cannabinoid (5F-ADB) detected in blood at low concentration

A case report documented a 45-year-old male driver impaired by the synthetic cannabinoid 5F-ADB, with the metabolite detected in blood at 26.37 ng/mL and no other drugs present, representing one of the first cases conclusively linking synthetic cannabinoids to driving impairment.

McCain, K R et al.·Journal of forensic science & criminology·2018·Preliminary EvidenceCase Report
RTHC-01754Case ReportPreliminary Evidence2018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Case Report
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Law enforcement witnessed erratic driving by a 45-year-old male in fall 2017. Roadside evaluation concluded the driver was intoxicated.

Comprehensive toxicology analysis found no alcohol, THC, or other drugs in the driver's blood.

Gas chromatography-mass spectrometry analysis of cigarettes found in the vehicle detected the synthetic cannabinoid 5F-ADB (also known as 5F-MDMB-PINACA).

Forensic LC-MS/MS testing detected the 5F-ADB metabolite 7 in the driver's blood at 26.37 ng/mL, with no other drugs present.

This represented one of the first cases conclusively demonstrating that synthetic cannabinoids ("K2" or "Spice") can significantly impair driving at relatively low concentrations.

Key Numbers

5F-ADB metabolite 7 detected at 26.37 ng/mL in blood. No other drugs detected. Driver was 45 years old.

How They Did This

Case report with comprehensive toxicology. Cigarette analysis by GC-MS. Blood analysis by validated forensic LC-MS/MS. 5F-ADB metabolite 7 quantified at 26.37 ng/mL.

Why This Research Matters

Standard drug testing often misses synthetic cannabinoids because they are structurally different from THC. This case demonstrates that impaired drivers can test "clean" on routine screens while being significantly impaired by potent synthetic compounds, highlighting the need for expanded testing panels.

The Bigger Picture

Synthetic cannabinoids are much more potent than natural cannabis, and new compounds are constantly being developed. Traffic safety testing has not kept pace with these developments, meaning many impaired drivers may be escaping detection.

What This Study Doesn't Tell Us

Single case report. No established impairment threshold for 5F-ADB. No cognitive or psychomotor testing was performed to quantify the degree of impairment. The metabolite concentration may not correlate linearly with impairment.

Questions This Raises

  • ?What blood concentration of 5F-ADB or its metabolites constitutes impairment?
  • ?How many DUI cases involve undetected synthetic cannabinoids?
  • ?Should standard roadside drug panels be expanded to include synthetic cannabinoids?

Trust & Context

Key Stat:
5F-ADB metabolite at 26.37 ng/mL with no other drugs, conclusively linked to driving impairment
Evidence Grade:
Preliminary. Single case report with thorough toxicological analysis, but no established impairment thresholds for this compound.
Study Age:
Published in 2018. 5F-ADB has since been associated with numerous deaths and adverse events. Synthetic cannabinoid detection in forensic settings has improved.
Original Title:
Impaired Driving Associated with the Synthetic Cannabinoid 5f-Adb.
Published In:
Journal of forensic science & criminology, 6(1) (2018)
Database ID:
RTHC-01754

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Describes what happened to one person or a small group.

What do these levels mean? →

Frequently Asked Questions

What is 5F-ADB?

5F-ADB (also called 5F-MDMB-PINACA) is a potent synthetic cannabinoid that acts as a full agonist at cannabinoid receptors. It is much more potent than THC and has been associated with severe adverse effects including deaths. It is commonly found in products sold as "K2" or "Spice."

Why was not the synthetic cannabinoid detected by standard drug testing?

Standard drug tests are designed to detect THC and its metabolites. Synthetic cannabinoids have different chemical structures that do not trigger positive results on conventional immunoassay screens. Specialized testing (like LC-MS/MS) is needed to identify specific synthetic compounds.

Read More on RethinkTHC

Cite This Study

RTHC-01754·https://rethinkthc.com/research/RTHC-01754

APA

McCain, K R; Jones, J O; Chilbert, K T; Patton, A L; James, L P; Moran, J H. (2018). Impaired Driving Associated with the Synthetic Cannabinoid 5f-Adb.. Journal of forensic science & criminology, 6(1). https://doi.org/10.15744/2348-9804.6.105

MLA

McCain, K R, et al. "Impaired Driving Associated with the Synthetic Cannabinoid 5f-Adb.." Journal of forensic science & criminology, 2018. https://doi.org/10.15744/2348-9804.6.105

RethinkTHC

RethinkTHC Research Database. "Impaired Driving Associated with the Synthetic Cannabinoid 5..." RTHC-01754. Retrieved from https://rethinkthc.com/research/mccain-2018-impaired-driving-associated-with

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.